Shares of Positron Corporation (OTC: POSC), a leading molecular imaging healthcare company providing innovative nuclear medicine technologies and solutions, surged on Friday after the company announced the receipt of Nuclear Regulatory Commission (NRC) manufacturing and distribution license.�
POSC shares rose to an intra-day high of $0.03, before finishing the day 40.62% higher at $0.0225 on above average volume of 850,609 to 20.26 million.
Positron announced the approval of its NRC manufacturing and distribution license amendment for its radiopharmaceutical manufacturing facility in Crown Point, Indiana. POSC had received its pharmacy license from the Indiana Board of Pharmacy back in December 2011. The pharmacy license served as precursor to the NRC amendment and recent approval, enabling the company to manufacture and distribute radiochemicals and radiopharmaceuticals throughout the U.S.
Scott Stiffler, Vice President of Pharmaceuticals, said that the NRC approval completes the mandatory requirements qualifying POSC�s Crown Point site as a fully licensed and operational radiochemical manufacturing facility. Stiffler also said that the capabilities at the Crown Point facility will play an important rose in POSC�s expansion into radiopharmaceutical and radiochemical production and further development of products relevant to the company�s full solution strategy. He added that POSC expects sales of Idium Oxyquinoline to commence in the coming quarter.�
Positron is currently engaged in the production of Idium 111 Oxyquinoline for customer assessment and commercial sale, with plans to process additional radioisotopes for medical use.�
Related Articles:How Much Yield Can You Get From Junk?
Visa, MA: GAO Sees ! Status Q uo
Tags: 2014 Top Performing Stocks ,Top Performing Stocks For 2014 ,Top Performing Stocks To Invest In ,Best China Stocks 2012
No comments:
Post a Comment